A clinical impact of the XAF1 expression was already shown in epithelial ovarian cancer [22], pancreatic tumors [23], clear-cell renal cell cancer [27], and gastric adenocarcinomas [46]. This evidence concerns the gene XAF1 and clear cell renal carcinoma.